医薬品の開発に
「実りある」
患者・市民参画を育てる
Multi-stakeholder Co-creation
Social co-creation with patients and public
Inclusive and sustainable participation from diverse backgrounds
Equitable and reciprocal benefits
Ongoing opportunities for mutual learning – not just receiving support or making requests
Concrete actions
Robust planning to return value to society
Clinical Trial Ambassador Project
Empirical research 'Using PED as Evidence'
A pilot case study 'Building PED using metaverse'
Patient-focused clinical trial ecosystem
Supporting citizen science
Interdisciplinary Approach to Science
Empirical research activities that foster patient and public involvement (PPI)
A Focus on Societal Implementation
Consultation to implement PPI
We offer consultations on PPI
in medicines development and clinical research.
Our team—representing various professional backgrounds—works with
companies, researchers, healthcare providers, and patient groups
to help put PPI into practice.
Participation in PFMD's initiative
Patient engagement and patient experience data
Patient engagement in health technology assessment
Global clinical trials ecosystem
Co-hosted by 1st PEOF+ Asia Pacific in Manila in 2026.
A Global Perspective
Systematizing PPI through international collaboration
Our Milestones
2020 In Austria, Boehringer Ingelheim and European Patients' Academy on Therapeutic Innovation jointly launch the Clinical Trial Ambassador Project. The first training program for patient organizations is delivered.
2021 Bringing Patient Education to Japan - Boehringer Ingelheim Japan, together with multiple patient organizations and researchers, comes together to design the Japan version of the Clinical Trial Ambassador Project.
2022 Beyondanscending organizational boundaries - Pharmaceutical companies, patient organizations, and researchers collaborate across organizational boundaries to deliver the first Clinical Trial Ambassador Training. Six patient participants complete the program and become Clinical Trial Ambassadors.
2024 Expanding Innovation to Society - To enhance the public value and credibility of the initiative, the project is formalized as a non-profit organization. On April 25, YORIAILab is established as a general incorporated association.
2025 Towards a Co-creation Community - To further advance patient and public involvement in healthcare and drug development, activities expand beyond the Clinical Trial Ambassador Project to include education, awareness, collaboration with domestic and international partners, and research. To date, 52 patients and members of the public complete the Clinical Trial Ambassador Training.
Highlights
New Resources ➡️
Meaningful Engagement
The discussion we presented at the Sequential Meetings - Consensus for Global Research Ethics and Meaningful Engagemen has been published in the December 2025 issue of Clinical Evaluation. YORIAILab endorses the Statement for Global REsearch Ethics Norm and Meaningful Engagement (GREEN Statement), which was adopted following a series of deliberations at the conference.
News
2026.4.7
We have compiled a list of publicly accessible resources for learning about medicines development. Each resource is accompanied by information on its intended audience. This list was created as one of the outputs of the 2025 internship program.
-
List of Resources for Learning about Medicines Development (Japanese) ➡️
2026.4.18
At the Japanese Society for Clinical Trials Symposium (co-sponsored by the CTX Research Group), titled "Current Status and Challenges of DCT Promotion in Japan - Considering Contributions to Eliminating 'Drug/Device Lag and Loss'!", I gave a presentation entitled "DCT from a Patient's Perspective - Expectations and Challenges." I shared the results of the DCT workshops we conducted with 17 clinical trial ambassadors in February and March of this year.
2026.4.20
The 2026 Annual General Meeting of Members will be held on Tuesday, June 23rd (in-person and online). We ask all special members and general members (who are members with voting rights under the Act on General Incorporated Associations) to participate as much as possible. This year is the year for the election of board members. Following the general meeting, we will hold a Clinical Trial Ambassador Roundtable "YORIAI" (details TBD).
2026.3.31
The Ministry of Health, Labour and Welfare has issued "Regarding the Handling of Information Provision Related to Clinical Trials, etc." (dated March 30, 2026, Pharmaceutical and Mathematics Bureau Notification No. 0330-1) and two related notices (➡️ Access to Ministry of Health, Labour and Welfare documents).
Public consultation
Public comment collection on new systems and guidelines regarding patient and citizen participation
We are currently soliciting public comments on the following new laws and systems. Anyone can submit their opinion.
If you have any questions, please contact us here: ✉ nobutaka.yagi@yoriailab.com
